In Brief: Federal Trade Commission hearing
Federal Trade Commission hearing: On "how pharmaceutical research is changing to provide more competition with brand name drugs" will occur Oct. 23. The hearing is part of a series on whether "changing economic factors such as globalization and the growth of high-tech industries" necessitate adjustments to FTC's antitrust and consumer protection enforcement policies. The hearing will take place at FTC headquarters in Washington, D.C...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth